Use of
This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.
1. A method of treating an infectious disease in a subject having a Th2 phenotypic profile, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein said Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, wherein said Th2 phenotypic profile is parasite-induced, and wherein said administering produces a Th1 cell-mediated immune response in said subject.
2. The method of claim 1 , wherein said parasite is a helminth, or a protozoan parasite.
3. The method of claim 2 , wherein said helminth is Schistosoma mansoni.
4. The method of claim 2 , wherein said protozoan parasite is malaria, leishmania , toxoplasma.
5. The method of claim 1 , wherein said additional polypeptide is a non-hemolytic Listeriolysin O (LLO) polypeptide, an ActA polypeptide, or a PEST sequence.
6. The method of claim 1 , wherein said subject is human.
7. The method of claim 1 , wherein said antigen is an HIV antigen, a malaria antigen, or a tuberculosis antigen.
8. The method of claim 7 , wherein said antigen elicits an immune response to HIV-1 gag cytotoxic T lymphocyte or to HIV-1 gag T helper epitopes.
9. The method of claim 7 , wherein said HIV antigen is HIV-gag, pol, env, protease, rev, tat, nef, vif, or vpr.
10. The method of claim 7 , wherein said malaria antigen is circumsprozoite protein (CSP), sporozoite surface protein 2 (PfSSP), liver stage antigen 1 (LSA1), merozoite surface protein 1 (MSP-1), serine repeat antigen and AMA-1, Pfs25, schizont export protein, 19 repeats of the sprozoite surface protein (NANP), SPf66, recombinant (Asn-Ala-Pro15Asn-Val-Asp-Pro)2-Leu-Arg(R32LR) protein covalently bound to a purified Pseudomonas aeruginosa toxin, NYVAC-Pf7, (NANP)19-5.1, (RTS,S, RTS,S/AS01), or a combination thereof.
11. The method of claim 7 , wherein said tuberculosis antigen is ESAT-6, TB10.4, CFP10, RD1-ORF5, RD1-ORF2, Rv1036, MPB64, MPT64, Ag85A, Ag85B (MPT59), Mtb39, MPB59, Ag85C, 19 kDa lipoprotein, MPT32 and alpha-crystallin, EsxG, Rv2430c, Rv2041c, or at least on T-cell epitope of any of the above.
12. The method of claim 1 , further comprising the step of administering a booster vaccination.
13. The method of claim 12 , wherein said booster vaccination comprises a DNA vaccine encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a recombinant polypeptide comprising said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a viral vector encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof or a live recombinant Listeria vaccine vector.
14. The method of claim 1 , wherein said Th1 immune response is a cytotoxic T-cell response or a memory T-cell response.
15. The method of claim 1 , wherein said Listeria vaccine vector is a recombinant auxotrophic dal/dat mutant Listeria strain.
16. The method of claim 1 , wherein said Listeria vaccine vector comprises an actA gene mutation.
17. The method of claim 1 , wherein said Listeria vaccine vector comprises an inlB gene mutation.
18. The method of claim 1 , wherein said Listeria vaccine vector comprises an actA and inlB gene mutation.
19. The method of claim 1 , wherein said immune response is against an infectious disease in said subject.
20. The method of claim 1 , wherein said infectious disease is amebiasis, an HIV infection, a malaria infection, a leishmania infection, a trichuris infection, or a tuberculosis infection.
21. The method of claim 1 , wherein said subject having a Th2 phenotypic profile is Th1 unresponsive.
22. The method of claim 21 , wherein Th1 response indicators in said subject are reduced or absent.
23. The method of claim 1 , wherein said subject having a Th2 phenotypic profile is Th2 biased and immune suppressed prior to treatment with said Listeria vaccine vector.
24. The method of claim 23 , wherein said subject having a Th2 phenotypic profile has a reduction in IFN-gamma production, an elevation in the level of IL-4, or an elevation in the level of IL-10, prior to treatment with said Listeria vaccine vector.